Venus Remedies informed the exchanges on December 6 that it has received the marketing authorisation for Pemetrexed 500mg, a chemotherapeutic agent widely used in the treatment of lung cancer and mesothelioma.
Venus Remedies informed the exchanges on December 6 that it has received the marketing authorisation for Pemetrexed 500mg, a chemotherapeutic agent widely used in the treatment of lung cancer and mesothelioma.